Torrent Pharma has  reported earnings results. According to the results, Profit before tax rose 29.7pc to Rs 384 crore in Q2 September 2020 as against Rs 296 crore in Q2 September 2019. The Company's Total tax expense for the quarter rose 42.31pc to Rs 74 crore as against Rs 52 crore in Q2 September 2019. The second result was declared after trading hours yesterday, 26 October 2020. Earnings before interest, taxes, depreciation, and amortization, rose 12pc to Rs 641 crore in Q2 FY21 as against Rs 573 crore in Q2 FY20, driven by recovery in India and productivity gains. Earnings before interest, taxes, depreciation, and amortization, margin improved to 32pc in Q2 FY21 from 12pc in Q2 FY20.

Gross profit fell marginally 0.27pc to Rs 1,463 crore  in Q2 FY21 as against Rs 1,467 crorein Q2 FY20. Research & Development (R&D) spend slipped 8pc to Rs 119 crore in Q2 FY21 as against Rs 130 crore in Q2 FY20.  In India, the sub-chronic and acute segments witnessed gradual recovery during the quarter while chronic momentum continued. Field Force productivity  for the quarter stood at Rs 8 lakh with an MR strength of 4,000. Globally, US revenues slipped 14pc  year-on-year to Rs 327 crore in Q2 FY21, Brazil revenues skid 18pc to Rs 129 crore in Q2 FY21 while Germany revenues advanced 4pc Y-o-Y to Rs 261 crore in Q2 September 2020.

During mid morning session, Shares of Torrent Pharmaceuticals declined 2.59pc to Rs 2,587 on NSE. As per company profile, Torrent Pharmaceuticals, is the flagship company of the Torrent Group. Torrent Pharma is amongst the top  FIVE in the therapeutics segments of Cardiovascular, Central Nervous System, Gastro intestinal), and Vitamins Minerals Nutritional.